Role of Frailty in Assessing Eligibility for CAR T-Cell Therapy in Haematology.

ABSTRACT:

Background and objectives

Frailty is a key consideration in determining whether a patient is robust enough for CAR T-cell therapy; however, it should not represent a barrier to treatment. Our study aimed to describe the extent of research concerning frailty in haematology adult and paediatric patients being considered for CAR T-cell therapy and its potential impact on their eligibility.

Methods

Following the Joanna Briggs Institute guidelines, we adopted a scoping review methodology. Our search was conducted across the databases CINAHL, Cochrane, Embase, Medline, PubMed, Google Scholar, clinicaltrials.gov, clinical trials register.eu, and euclinicaltrials.eu for studies published from 2017 to March 2nd 2024. Studies were screened by independent teams of reviewers using the w

SUBMITTER: Clesham J 

PROVIDER: S-EPMC12673358 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature